Research Paper Volume 11, Issue 17 pp 7123—7149
Chromobox homolog 8 (CBX8) Interacts with Y-Box binding protein 1 (YBX1) to promote cellular proliferation in hepatocellular carcinoma cells
- 1 State Key Laboratory of Organ Failure Research, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
- 2 Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
- 3 Department of Infectious Diseases, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China
- 4 Department of Radiation Oncology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China
- 5 Department of Oncology, The Second Affiliated Hospital, Guizhou Medical University, Kaili, P.R. China
- 6 Department of Medical Oncology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
How to Cite
Polycomb group (PcG) proteins have recently been identified as critical regulators in tumor initiation and development. However, the function of CBX8 in human hepatocellular carcinoma (HCC) remains largely unknown. Our study was designed to explore the biological function and clinical implication of CBX8 in HCC. We investigated the interplay between CBX8 and cell cycle through Gene Set Enrichment Analysis and western blotting. Bioinformatics tools and co-immunoprecipitation were used to explore cell cycle regulation. Finally, we studied the expression and clinical significance of CBX8 in HCC through 3 independent datasets. CBX8 was upregulated in HCC and its expression correlated with cell cycle progression. CyclinD1 was downregulated by CBX8 knockdown but upregulated by CBX8 overexpression. YBX1 interacted with CBX8 and regulated the cell cycle. Moreover, targeting YBX1 with specific siRNA impaired CBX8-mediated regulation of CyclinD1. CBX8 overexpression boosted HCC cell growth, while CBX8 knockdown suppressed cell proliferation. Further, YBX1 interacted with CBX8. YBX1 knockdown compromised the proliferation of CBX8 overexpressing cells. CBX8 promotes HCC cell proliferation through YBX1 mediated cell cycle progression and is related to poor HCC prognoses. Therefore, CBX8 may serve as a potential target for the diagnosis and treatment of HCC.
IntroductionLiver cancer was predicted to be the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality worldwide in 2018, with about 841,000 new cases and 782,000 deaths annually . Hepatocellular carcinoma (HCC), accounting for most (75%–85%) of the primary liver cancers occurring worldwide, remains one of the most prevalent and deadliest human cancers . Despite improvements in surgical resection, liver transplantation, molecular-targeted therapy and immunotherapy, the prognosis of HCC has still remained poor over the last decades [2–4]. HCC is typically diagnosed at an advanced stage and has shown a high recurrence rate, resulting in adverse outcomes in patients . Therefore, it is critical to clarify the molecular mechanisms underlying HCC progression and identify novel therapeutic targets for HCC treatment. Among pathways and factors involved in the formation and maintenance, the PcG proteins have garnered the attention of researchers [6, 7]. Deregulation and dysfunction of PcG proteins often lead to blockade or inappropriate activation of developmental pathways, enhancement of cellular proliferation, inhibition of apoptosis, and restoration of the cancer stem cell population [7–10]. PcG proteins function principally as two large multisubunit complexes, Polycomb repressive complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2) . Under normal circumstances, PRC1 maintains the histone methylation induced by PRC2 to pass on the inactivation signals where CBX8, also known as human Polycomb 3 (HPC3), functions as a transcriptional repressor as part of PRC1 . CBX8 was shown to inhibit the expression of INK4a/ARF to bypass cell senescence in fibroblasts . PcG proteins have been also shown to exhibit non-polycomb functions, contributing to the regulation of diverse cellular functions [7, 12–14]. Recently, CBX8 has been demonstrated to exhibit oncogenic functions in a non-canonical manner in human malignancies. For instance, Cbx8 acts non-canonically with Wdr5 to promote mammary tumorigenesis . Recently, abnormal expression of CBX8 in multiple tumors was reported. CBX8 play different roles in different tumors [6, 15–21]. However, the mechanism by which CBX8 regulates the malignant growth of HCC remains unclear. In our study, we aim to explore the expression of CBX8 in HCC and its clinical significance by gene microarrays and bioinformatics tools. To further explore the mechanism by which CBX8 plays a role in HCC, we examined the direct coupling of proteins through bioinformatics tools and co-immunoprecipitation (Co-IP) experiments. Finally, we investigated the biological function of CBX8 in HCC cells through CCK-8, and EdU experiments. We set out to identify the mechanism by which CBX8 regulates the malignant progression of HCC. An additional goal is to understand whether CBX8 can be used as a target to block the malignant progression of HCC.
CBX8 is positively correlated with cell cycle signaling pathwayTo dissect the molecular mechanism of CBX8, we carried out Gene Set Enrichment Analysis (GSEA) of The Cancer Genome Atlas (TCGA) cohort and found that CBX8 high expressing groups were enriched for cell cycle-related gene sets (Figure 1A and 1B). To confirm its function in regulating the cell cycle, we detected a series of cell cycle-related genes after interfering with CBX8 and found that CCND1 was significantly down-regulated (Figure 1D, Supplementary Figure 1A), and that CyclinD1 was down-regulated by CBX8-knockdown at the protein level (Figure 1C).
Figure 1. CBX8 is positively correlated with cell cycle signaling pathway. (A–B) Results of Gene Set Enrichment Analysis (GSEA) were plotted to visualize the correlations between CBX8 cell cycle gene signatures in the TCGA cohort (P < 0.01). (C–D) Both protein and mRNA levels of CyclinD1 in CBX8 Knockdown Huh7 cells, as detected by western blotting and q-RT-PCR.
CBX8 interact with YBX1In order to unveil the mechanism underlying the oncogenic function of CBX8 in modulating the cell cycle, we searched for proteins predicted to interact with CBX8 through BioGRID (https://thebiogrid.org/) as well as in the literature, and found that CBX8 may bind to YBX1, ILF3(Interleukin Enhancer Binding Factor 3), TFCP2 (Transcription Factor CP2) and UBE2S (Ubiquitin Conjugating Enzyme E2S) (Figure 2A) . To confirm their interaction, we first tested the correlation between their mRNA expression levels in HCC. As detected in TCGA cohort, CBX8 expression was positively correlated with YBX1 and UBE2S mRNA levels (Figure 2B and Supplementary Figure 2A–2C) (r = 0.3167; P< 0.001 and r=0.3190; P=0.0001). More importantly, it was demonstrated via co-immunoprecipitation (Co-IP) experiments that CBX8 interacted with YBX1 (Figure 2C–2D), rather than with ILF3, TFCP, UBE2S (Supplementary Figure 2D).
Figure 2. CBX8 interacts with YBX1 (A) CBX8 may interact with YBX1, as visualized by BioGRID. (B) Correlation between CBX8 mRNA and YBX1 mRNA in TCGA cohort (P = 0.0001). (C) Huh7 cells were transfected with Flag-CBX8 overexpression vector for 48 h. An immunoprecipitation (IP) assay, using an anti-Flag antibody, was used to detect the binding of CBX8 and YBX1. (D) Huh7 cells were transfected with GFP-CBX8 and Flag-YBX1 overexpression vector for 48 h. An IP assay, using an anti-Flag antibody, was used to detect the binding of CBX8 and YBX1.
CBX8 increase levels of CyclinD1 through YBX1We explored whether CBX8 can play a role in promoting the cell cycle through YBX1 in HCC cells. Firstly, GSEA results showed that YBX1 targets were enriched in high CBX8 expressing groups (Figure 3A) and YBX1 expression was positively correlated with the cell cycle related genes (Figure 3B). To confirm the association of CBX8 with YBX1 and the cell cycle, we transfected a plasmid containing the CBX8 sequence in Huh7, MHCC-97H and SK-Hep-1 cells, and found that CBX8 overexpression markedly increased the level of CyclinD1, while knockdown of YBX1 with a specific siRNA abrogated its effect (Figure 3C–3D, Supplementary Figure 3A). Moreover, CCND1, the mRNA encoding for CyclinD1, was also regulated by CBX8 and YBX1 in the same manner (Figure 3E–3F, Supplementary Figure 3B). Moreover, when we interfered with CBX8 and simultaneously overexpressed YBX1 in Huh7 cells, YBX1 rescued the down-regulation of CBX8-induced CCND1 down-regulation (Supplementary Figure 3C). Therefore, CBX8 promotes the expression of CyclinD1 in a YBX1-dependent manner.
Figure 3. CBX8 increase levels of CyclinD1 through YBX1. Results of GSEA were plotted to visualize the correlation between the expression of CBX8 (A) or YBX1 (B) and gene signatures of YBX1 target up or KEGG cell cycle in the TCGA cohort (P < 0.01). (C–F) Both protein and mRNA levels of CyclinD1 in Huh7 and MHCC-97H cells-overexpressing CBX8 or YBX1 knock-down as detected by western blotting and q-RT-PCR.
CBX8 promotes HCC cell proliferation in vitro and in vivoNext, whether CBX8 plays a role in the cell proliferation was evaluated. As depicted by CCK-8 and EdU assay, MHCC-97H cells overexpressing CBX8 showed enhanced proliferation compared with the control group (Figure 4A–4C). Another two HCC cell lines, Huh7 and SK-Hep-1 also showed increased cell growth after overexpressing CBX8 (Figure 4D–4F, Supplementary Figure 4A–4C).
Figure 4. CBX8 overexpression promotes cell proliferation. (A and D) Cell proliferation was evaluated by the CCK-8 assay. (B–F) Effect of CBX8 on cell proliferation as measured by EdU assays *P < 0.05; **P < 0.01;***P < 0.001.
Figure 5. Knockdown of CBX8 dramatically decreases the cell proliferation in vitro. (A and B) Cell proliferation was evaluated by the CCK-8 assay. (C–F) Effect of CBX8 on cell proliferation as measured by EdU assays *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 6. Knockdown of CBX8 dramatically decreases cell proliferation in vivo (A) Representative images of tumors formed in nude mice subcutaneously injected with CBX8–silenced MHCC-97H cells. (B) Tumor weights (***P <0.001). (C) Tumors induced by CBX8 silencing in MHCC-97H cells (***P <0.001) showed markedly lower growth rates than the control cells.
CBX8 promotes HCC cell proliferation through YBX1Given that CBX8 regulated CyclinD1 expression through YBX1, we hypothesize that its regulatory function in cell proliferation is YBX1-dependent. We repeated the EdU assay in Huh7, MHCC-97H and SK-Hep-1 cells overexpressing CBX8 with or without simultaneous knockdown of YBX1 with targeted siRNA. Results showed that the increased proliferation of Huh7, MHCC-97H and SK-Hep-1 cells induced by CBX8 overexpression was attenuated by interfering YBX1 (Figure 7A–7D, Supplementary Figure 7A, 7C). Furthermore, when we interfered with CBX8 and simultaneously overexpressed YBX1 in Huh7 cells, YBX1 rescued the effect of CBX8 down-regulation on the inhibition of cell proliferation (Supplementary Figure 7B, 7D). These results confirm that CBX8 promoted cell proliferation in a YBX1-dependent manner.
CBX8 expression is up-regulated in HCC and is correlated with prognosisAs CBX8 plays a significant role in cell proliferation, we next explored its clinical importance. Clinical data of a cohort containing 369 HCC cases and 50 non-tumor cases were obtained from TCGA website (https://www.cancer.gov), and analysis revealed that CBX8 was upregulated in HCC lesions when compared with normal tissues (Figure 8A). We also analyzed another cohort (GSE14520) from GEO database and discovered that in comparison with non-tumor tissues, HCC lesions exhibited higher levels of CBX8 mRNA (Figure 8B). To confirm these results, we compared its expression in 8 pairs of HCC tissues and adjacent normal liver tissues. Accordingly, CBX8 was overexpressed at both mRNA and protein levels in the tumor (Figure 8C–8D). Not only in HCC, but CBX8 expression was increased in pan-cancer as compared with the corresponding non-tumor tissues (Supplementary Figure 8A).
Figure 8. CBX8 expression is up-regulated in HCC and is correlated with poor prognosis. (A–B) Expression of CBX8 in the TCGA and GSE14520 cohorts (P < 0.001) (C) Expression levels of CBX8 in HCC tissues and adjacent non-tumor tissues (NFYY cohort) as measured by qRT-PCR analysis (P < 0.05); β-actin was used as an internal control. Data are shown as median with interquartile range. (D) The protein expression of CBX8 in 8 HCC samples was determined by western blotting. (E, F) Kaplan-Meier analysis of the overall and disease-free survival in the TCGA cohort based on CBX8 expression (G, H) Kaplan-Meier analysis of the overall and disease-free survival in the TCGA cohort based on CBX8 and YBX1 expression.
DiscussionThe key finding of the current study was that CBX8 promotes cell proliferation and the cell-cycle progression by interacting with YBX1. Our results showed that CBX8 is overexpressed in HCC tissues as compared to corresponding adjacent non-tumor tissues from 3 independent cohorts. Moreover, patients with simultaneous overexpression of CBX8 and YBX1 featured shorter survival and poorer prognosis. Thus, our results indicated that CBX8 may serve as a potential target for the diagnosis and treatment of patients with HCC. Dysregulation of CBX8 has been reported in various human cancers [15, 16, 20–22, 24]. Growing research has shown the cell proliferation promoting effects of CBX8 in different types of cancers [15, 18, 20]. Unlashed cell proliferation is the hallmark of cancer, and tumor cells have typically acquired damage of genes that directly regulate their cell cycles [25, 26]. Genetic alterations affecting Cyclin D1, and control exit from the G1 phase of the cell cycle, are frequently documented in human cancers and inactivation of this pathway may as well be necessary for tumor development [25, 27]. Interestingly, we found that CBX8 is involved in the cell cycle signaling pathway and regulates the expression of CyclinD1 in HCC cells. Also, our research found that CBX8 regulated the cell cycle through YBX1. The Y-box binding protein (YBX1) is known to be a multifunctional transcription and translation factor regulating protein expression; its aberrant activation thus influences various malignant phenotypes of cancer cells [28–32]. For example, it is involved in promoting cancer progression, cell proliferation and multidrug resistance [29, 32–34]. Our study uncovered its interaction with CBX8. Their interaction was predicted by bioinformatics tools and further confirmed with Co-IP and other experiments. Moreover, the function of CBX8 in driving the cell cycle progression and cell proliferation was impaired upon YBX1 knockdown. Therefore, we summarized that CBX8 regulates the cell cycle progression through YBX1 in HCC. We also found distinctive upregulation of CBX8 in fresh tissues, identified by qRT-PCR and western blot analyses. In TCGA cohorts, patients with high CBX8 expression experienced significantly shorter overall and disease-free survival, as compared with the low CBX8 expression group. Taken together, these findings suggested the misregulation of CBX8 is a potential biomarker for clinical surveillance of tumor progression. Zhang’s and Bo Tang’s reports are consistent with our results and have further confirmed the reliability of our results. However, the mechanisms of malignant HCC progression are different [18, 22]. We first found a new important binding partner for CBX8, and found that CBX8 regulates the proliferation of HCC cells through the regulation of cell cycle pathways. Moreover, we discovered that CBX8 represent a better predictor for poor prognosis of tumors, especially in case of staging, co-occurrence with hepatitis, and when the tumor is treated with sorafenib. More importantly, we found that the simultaneous overexpression of CBX8 and YBX1 is an excellent predictor of poor prognosis in HCC cases. This novel marker may serve as a potential target for the diagnosis and treatment of patients with HCC in the future. In summary, we identified CBX8 as an oncogene with prognostic significance in HCC. CBX8 promotes HCC progression through activating the expression of CyclinD1 by binding to YBX1. Our study provides, for further evaluation, a novel therapeutic target for hepatocellular carcinoma treatment. However, our research also has some limitations, for example, the lack of multi-center and large sample sets for verification, limits the validity of our findings. In the future, more clinical samples will be used to verify the results. Moreover, the mechanisms surrounding CBX8 need further exploration, such as the mechanisms by which CBX8 affects CyclinD1 through YBX1. Of note, synthetic inhibitors are also essential tools to explore the role of CBX8 in HCC. For instance, inhibitors of EZH2, a vital member of the PRC2 complex, play a role in multiple tumors, and specific inhibitors are currently under clinical trial [35–40].
Materials and Methods
Human HCC samples“NFYY cohort”: HCC samples and paired noncancerous specimens from 8 HCC patients who underwent hepatectomies between January 2012 and January 2013 at Nan fang Hospital, Southern Medical University (Guangzhou, China) were included in this study. Tissues were frozen with liquid nitrogen instantly after hepatectomies and stored in a refrigerator at −80°C. The study was reviewed and approved by the Nan fang Hospital Institutional Review Board.
Cell linesSK-Hep-1, Huh7 and MHCC-97H cells were obtained from the Cell Bank of Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). Cells were cultured under the conditions advised by the supplier.
Animal studiesA subcutaneous xenograft model was established to determine the effect of CBX8 on tumor growth in vivo. BALB/c nude mice (males, 4–5-weeks-old) were purchased from the Central Laboratory of Animal Science, Southern Medical University (Guangzhou, China). Experimental procedures in this study were performed according to our institutional guidelines for using laboratory animals and were approved by the Institutional Animal Care and Use Committee of Nanfang Hospital. In total, 1 × 107 MHCC-97H, SK-Hep-1 stably expressing sh-CBX8, and vector control were subcutaneously injected into the flank of the mice (Genechem Company Ltd., Shanghai, China). After 25 days, the mice were sacrificed. Tumor growth was examined every 2-3 days. Tumors were weighed after removal.
Bioinformatics analysis“TCGA cohort”: A cohort from the TCGA (https://tcga-data.nci.nih.gov/tcga/) database including 369 HCC patients with CBX8 and YBX1 as well as follow-up information was included in our study to explore the expression levels of CBX8 and YBX1 in HCC. (Overall survival) OS and (Disease-free survival) DFS were also assessed according to CBX8 or YBX1 expression levels as follows: patients were split into two groups on the basis of CBX8- expression status in the primary tumor. Those with a CBX8-expression level ranked in the top quartile were classified into the high expression group and the rest into the low expression group [41–43]. “GSE14520 cohorts”: microarray data (GEO accession numbers GSE14520 were down loaded from the GEO (http://www.ncbi.nlm.nih.gov/geo/) to validate CBX8 or YBX1 expression level in HCC.  GCBI (Gene-Cloud of Biotechnology Information) (Shanghai, China, https://www.gcbi.com.cn) is a data analysis website. In this study, we used GCBI to identify relative CBX8 mRNA expression in human cancers. Stratified analysis showed the correlation of CBX8 or YBX1 and survival in liver cancers was analyzed in Kaplan–Meier Plotter (http://kmplot.com/analysis/) . CCK-8 and EdU Assays, qRT-PCR, Plasmid Construction and Transient Transfection, Western Blot, RNA interference, Co-Immunoprecipitation (Co-IP), Lentiviral Construction and Cell Transfection; these were performed as described previously and are detailed in the Supplementary Methods.
Statistical analysisData are presented as the mean ± standard error of the mean (SEM) from three independent experiments, except when indicated otherwise. The t-test or one-way analysis of variance (ANOVA) for comparison of two groups, multi-way classification ANOVA for cell proliferation, Pearson’s correlation for analyzing the correlation between CBX8 and YBX1, and Kaplan-Meier for the survival analysis were used in this study. Statistical analyses were performed using SPSS 21.0 software (Abbott Laboratories, North Chicago, IL, USA). A P < 0.05 (two-tailed) was considered statistically significant.
Li Liu, Jin-Lin Hou and Lushan Xiao designed the study. Lushan Xiao, Wenwen Li, Qingcan Sun and Lushan Xiao performed the experiments. Lushan Xiao drafted the manuscript. Jingyuan Sun and hui-chuan Cao helped to draft the manuscript. Hongbo Zhu and Yang Song conducted the statistical analyses. Dehua Wu, Zixiao Zhou, Jie Peng and Dong Zhongyi revised the manuscript. All authors read and approved the final manuscript
We wish to thank all our colleagues in the Department of Infectious Diseases, Nan fang Hospital, Southern Medical University. We would like to thank Editage [www.editage.cn] for English language editing.
Conflicts of Interest
The authors declare no conflicts of interest.
This work was supported by the National Nature Science Foundation of China (Grant Nos. 81773008, 81672756, 81702390, 81872399, 81972897 and 81802863), Guangdong province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province (Grant Nos. 2017A030310105, 2017A030311023, and 2018030310285), the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (Grant No. 2017J003) and Guangzhou Technology Project (No.201804010044).
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 [PubMed]
- 2. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome. World J Hepatol. 2015; 7:1157–67. https://doi.org/10.4254/wjh.v7.i9.1157 [PubMed]
- 3. Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: from diagnosis to treatment. World J Hepatol. 2015; 7:1020–29. https://doi.org/10.4254/wjh.v7.i8.1020 [PubMed]
- 4. Kudo M. Systemic Therapy for Hepatocellular Carcinoma: latest Advances. Cancers (Basel). 2018; 10:10. https://doi.org/10.3390/cancers10110412 [PubMed]
- 5. Zeng S, Zhang Y, Ma J, Deng G, Qu Y, Guo C, Han Y, Yin L, Cai C, Li Y, Wang G, Bonkovsky HL, Shen H. BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2. Cancer Lett. 2017; 390:67–76. https://doi.org/10.1016/j.canlet.2016.12.042 [PubMed]
- 6. Gao SB, Sun SL, Zheng QL, Zhang L, Zhu Y, Jin GH, Xue LX. Genetic alteration and misexpression of Polycomb group genes in hepatocellular carcinoma. Am J Cancer Res. 2015; 5:2969–79. [PubMed]
- 7. Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R, and Polycomb Group. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev. 2015; 35:1220–67. https://doi.org/10.1002/med.21358 [PubMed]
- 8. Chan HL, Beckedorff F, Zhang Y, Garcia-Huidobro J, Jiang H, Colaprico A, Bilbao D, Figueroa ME, LaCava J, Shiekhattar R, Morey L. Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms. Nat Commun. 2018; 9:3377. https://doi.org/10.1038/s41467-018-05728-x [PubMed]
- 9. Gergely JE, Dorsey AE, Dimri GP, Dimri M. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells. Mol Carcinog. 2018; 57:831–41. https://doi.org/10.1002/mc.22804 [PubMed]
- 10. Santanach A, Blanco E, Jiang H, Molloy KR, Sansó M, LaCava J, Morey L, Di Croce L. The Polycomb group protein CBX6 is an essential regulator of embryonic stem cell identity. Nat Commun. 2017; 8:1235. https://doi.org/10.1038/s41467-017-01464-w [PubMed]
- 11. Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J, Helin K, Hansen KH. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J. 2007; 26:1637–48. https://doi.org/10.1038/sj.emboj.7601632 [PubMed]
- 12. Shen J, Li P, Shao X, Yang Y, Liu X, Feng M, Yu Q, Hu R, Wang Z. The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival. Cancer Res. 2018; 78:359–71. https://doi.org/10.1158/0008-5472.CAN-17-1805 [PubMed]
- 13. Waterfall JJ, Meltzer PS. A Non-canonical Polycomb Dependency in Synovial Sarcoma. Cancer Cell. 2018; 33:344–46. https://doi.org/10.1016/j.ccell.2018.02.013 [PubMed]
- 14. Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, Song G, Mi W, Wang RF, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun. 2018; 9:500. https://doi.org/10.1038/s41467-018-02863-3 [PubMed]
- 15. Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF, Brown BD, Gaspar-Maia A, Bernstein E. Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Rep. 2016; 16:472–86. https://doi.org/10.1016/j.celrep.2016.06.002 [PubMed]
- 16. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell. 2011; 20:563–75. https://doi.org/10.1016/j.ccr.2011.09.008 [PubMed]
- 17. Wang G, Tang J, Zhan W, Zhang R, Zhang M, Liao D, Wang X, Wu Y, Kang T. CBX8 Suppresses Tumor Metastasis via Repressing Snail in Esophageal Squamous Cell Carcinoma. Theranostics. 2017; 7:3478–88. https://doi.org/10.7150/thno.20717 [PubMed]
- 18. Zhang CZ, Chen SL, Wang CH, He YF, Yang X, Xie D, Yun JP. CBX8 Exhibits Oncogenic Activity via AKT/β-Catenin Activation in Hepatocellular Carcinoma. Cancer Res. 2018; 78:51–63. https://doi.org/10.1158/0008-5472.CAN-17-0700 [PubMed]
- 19. Yuan GJ, Chen X, Lu J, Feng ZH, Chen SL, Chen RX, Wei WS, Zhou FJ, Xie D. Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway. Cancer Sci. 2017; 108:2166–75. https://doi.org/10.1111/cas.13383 [PubMed]
- 20. Tang J, Wang G, Zhang M, Li FY, Sang Y, Wang B, Hu K, Wu Y, Luo R, Liao D, Cao J, Wang X, Wang L, et al. Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. Oncotarget. 2014; 5:10778–90. https://doi.org/10.18632/oncotarget.2502 [PubMed]
- 21. Lee SH, Um SJ, Kim EJ. CBX8 suppresses Sirtinol-induced premature senescence in human breast cancer cells via cooperation with SIRT1. Cancer Lett. 2013; 335:397–403. https://doi.org/10.1016/j.canlet.2013.02.051 [PubMed]
- 22. Tang B, Tian Y, Liao Y, Li Z, Yu S, Su H, Zhong F, Yuan G, Wang Y, Yu H, Tomlinson S, Qiu X, He S. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis. 2019; 10:52. https://doi.org/10.1038/s41419-018-1288-0 [PubMed]
- 23. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006; 34:D535–39. https://doi.org/10.1093/nar/gkj109 [PubMed]
- 24. Ning G, Huang YL, Zhen LM, Xu WX, Jiao Q, Yang FJ, Wu LN, Zheng YY, Song J, Wang YS, Xie C, Peng L. Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients. Aging (Albany NY). 2018; 10:3450–73. https://doi.org/10.18632/aging.101658 [PubMed]
- 25. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672–77. https://doi.org/10.1126/science.274.5293.1672 [PubMed]
- 26. Lee Y, Lahens NF, Zhang S, Bedont J, Field JM, Sehgal A. G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. PLoS Biol. 2019; 17:e3000228. https://doi.org/10.1371/journal.pbio.3000228 [PubMed]
- 27. Peyressatre M, Prével C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 2015; 7:179–237. https://doi.org/10.3390/cancers7010179 [PubMed]
- 28. El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D, Kyle AH, Baker JH, LePard NE, et al. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. Cancer Cell. 2015; 27:682–97. https://doi.org/10.1016/j.ccell.2015.04.003 [PubMed]
- 29. Maurya PK, Mishra A, Yadav BS, Singh S, Kumar P, Chaudhary A, Srivastava S, Murugesan SN, Mani A. Role of Y Box Protein-1 in cancer: as potential biomarker and novel therapeutic target. J Cancer. 2017; 8:1900–07. https://doi.org/10.7150/jca.17689 [PubMed]
- 30. Lu J, Li X, Wang F, Guo Y, Huang Y, Zhu H, Wang Y, Lu Y, Wang Z. YB-1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA-216a. Exp Cell Res. 2017; 359:319–26. https://doi.org/10.1016/j.yexcr.2017.07.039 [PubMed]
- 31. Zhao X, Liu Y, Yu S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim Biophys Acta Mol Basis Dis. 2017; 1863:1805–16. https://doi.org/10.1016/j.bbadis.2017.04.014 [PubMed]
- 32. Miao X, Wu Y, Wang Y, Zhu X, Yin H, He Y, Li C, Liu Y, Lu X, Chen Y, Shen R, Xu X, He S. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res. 2016; 346:157–66. https://doi.org/10.1016/j.yexcr.2016.07.003 [PubMed]
- 33. Maier E, Attenberger F, Tiwari A, Lettau K, Rebholz S, Fehrenbacher B, Schaller M, Gani C, Toulany M. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. Cancers (Basel). 2019; 11:11. https://doi.org/10.3390/cancers11040562 [PubMed]
- 34. Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019; 110:1536–43. https://doi.org/10.1111/cas.14006 [PubMed]
- 35. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018; 19:649–59. https://doi.org/10.1016/S1470-2045(18)30145-1 [PubMed]
- 36. Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun. 2018; 9:4116. https://doi.org/10.1038/s41467-018-06656-6 [PubMed]
- 37. Genta S, Pirosa MC, Stathis A. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer. Curr Oncol Rep. 2019; 21:13. https://doi.org/10.1007/s11912-019-0762-x [PubMed]
- 38. Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, Wan YY, Long H, Zhu B. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. Cancer Res. 2019; 79:2009–20. https://doi.org/10.1158/0008-5472.CAN-18-2395 [PubMed]
- 39. Velcheti V, Wong KK, Saunthararajah Y. EZH2 Inhibitors: Take It EZy, It Is All About Context. Cancer Discov. 2019; 9:472–75. https://doi.org/10.1158/2159-8290.CD-19-0090 [PubMed]
- 40. Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI, Qiao C, Nandakumar R, Cremers S, et al. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clin Cancer Res. 2019; 25:5271–83. https://doi.org/10.1158/1078-0432.CCR-18-3989 [PubMed]
- 41. Zhang DY, Zou XJ, Cao CH, Zhang T, Lei L, Qi XL, Liu L, Wu DH. Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma. Theranostics. 2018; 8:3751–65. https://doi.org/10.7150/thno.22493 [PubMed]
- 42. Hou Z, Zhao W, Zhou J, Shen L, Zhan P, Xu C, Chang C, Bi H, Zou J, Yao X, Huang R, Yu L, Yan J. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol. 2014; 53:380–88. https://doi.org/10.1016/j.biocel.2014.06.004 [PubMed]
- 43. Gómez-Maldonado L, Tiana M, Roche O, Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I, Favaro E, Moreno-Bueno G, Sanz L, Aragones J, Harris A, Volpert O, et al. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene. 2015; 34:2609–20. https://doi.org/10.1038/onc.2014.200 [PubMed]
- 44. Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018; 8:9227. https://doi.org/10.1038/s41598-018-27521-y [PubMed]